SCHEDULE 13G/A: XBiotech CEO John Simard Increases Beneficial Ownership to 19.9% Through Convertible Loan and Options

XBiotech Inc. CEO John Simard has increased his beneficial ownership in the company to 19.9% of common shares, primarily through a convertible loan and exercisable stock options.

Summary

• John Simard, President & CEO of XBiotech Inc., beneficially owns 6,624,530 common shares, representing 19.9% of the company's outstanding common stock as of December 31, 2024.
• This ownership includes 3,823,166 directly held shares, 870,381 shares from immediately exercisable stock options, and 1,930,983 shares convertible from a loan.
• The convertible loan, dated January 3, 2024, allows conversion at a fixed price of $4.048 per share, based on the average Nasdaq Official Closing Price for the five trading days preceding the loan agreement.
• The conversion of the loan is subject to a contractual cap, limiting Mr. Simard's total stock ownership to not exceed 19.9% of the company's issued and outstanding common stock at the time of conversion.
• Without this cap, the convertible loan would yield 2,470,355 shares, increasing Mr. Simard's total beneficial ownership to 7,163,902 shares.
• The percentage ownership is calculated based on 30,487,731 shares outstanding as of December 31, 2024, plus 2,801,364 shares issuable to Mr. Simard from options and the convertible loan, totaling 33,289,095 shares in the denominator.

Sentiment

Score: 8

Explanation: The document indicates a very strong positive sentiment due to the significant beneficial ownership by CEO John Simard, reaching 19.9% of the company. His provision of a convertible loan to the company further underscores his direct financial commitment and belief in XBiotech's future, aligning his interests closely with shareholders. This level of insider confidence is a strong positive signal.

Positives

• Increased insider ownership by the CEO, John Simard, to a significant 19.9% stake, signaling strong confidence in the company's future.
• The CEO's provision of a convertible loan to the company indicates direct financial support and alignment of interests with shareholders.
• The fixed conversion price of $4.048 per share for the convertible loan provides a clear valuation benchmark for the capital provided by the CEO.

Negatives

• The 19.9% ownership cap on the convertible loan conversion limits the potential for further direct equity infusion from the CEO beyond this threshold, potentially restricting future capital flexibility from this specific source.

Risks

• The value of the convertible loan shares is subject to the company's stock performance relative to the $4.048 conversion price.
• The 19.9% ownership cap could be perceived as a limitation on the CEO's ability to increase his stake further through this specific mechanism, potentially impacting future financing strategies if additional insider capital is needed from this source.

Future Outlook

The future outlook includes the potential conversion of the outstanding convertible loan balance into common stock at the election of John Simard, subject to a 19.9% ownership cap, which could further solidify his equity stake in the company.

Management Comments

• John Simard, President & CEO of XBiotech Inc., has certified the information set forth in this statement as true, complete, and correct to the best of his knowledge and belief.
• The convertible loan provided by the Reporting Person (John Simard) to the Issuer (XBiotech Inc.) under a convertible loan agreement dated January 3, 2024, demonstrates direct financial commitment from management.

Industry Context

This filing reflects a significant insider stake in a biotechnology company. High insider ownership, especially by the CEO, is often viewed positively in the biotech sector as it suggests strong belief in the company's pipeline and future prospects, which is crucial given the long development cycles and high risks inherent in the industry. It aligns management's interests directly with those of public shareholders.

Comparison to Industry Standards

• While specific comparable companies are not mentioned in the filing, a 19.9% beneficial ownership by a CEO is a substantial stake, often exceeding typical CEO ownership percentages in larger, more mature public companies.
• In smaller or development-stage biotech firms, such high insider ownership is more common and can be seen as a positive indicator of commitment and confidence, especially when it involves direct financial contributions like a convertible loan.
• This level of ownership suggests a founder-led or highly committed leadership structure, which can be a competitive advantage in terms of strategic focus and long-term vision compared to companies with more dispersed ownership.

Related Party Transactions

• A convertible loan agreement dated January 3, 2024, between XBiotech Inc. and its President & CEO, John Simard, constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The significant insider ownership by the CEO may instill greater confidence among existing and potential shareholders, signaling strong alignment of interests and belief in the company's long-term prospects.
• Employees: Strong insider commitment can contribute to a stable corporate environment, potentially benefiting employee morale and retention.
• Creditors: The convertible loan from the CEO could be viewed positively by creditors as it represents a direct financial commitment from leadership, potentially strengthening the company's financial position.

Next Steps

• Potential future conversion of the convertible loan into common stock by John Simard, subject to the 19.9% ownership cap.

Key Dates

Recommendation

Keywords

XBiotech Inc., John Simard, Schedule 13G, beneficial ownership, insider ownership, convertible loan, stock options, common shares, SEC filing, corporate governance, biotech, capital raise